Literature DB >> 16206298

Long-term disease-free survival of patients with radically resected thymomas: relevance of cell-cycle protein expression.

Tommaso Claudio Mineo1, Vincenzo Ambrogi, Davide Mineo, Alfonso Baldi.   

Abstract

BACKGROUND: Despite radical surgical resection, thymomas often recur. The objective of the current retrospective study was to investigate the prognostic relevance of the expression of cell-cycle proteins in these neoplasms to formulate a possible therapeutic surveillance strategy for the prevention of recurrence.
METHODS: The authors retrospectively reviewed the main clinicopathologic factors, including the World Health Organization (WHO) classification, of patients with thymoma who had undergone radical surgical resection. Specimens were studied using immunohistochemistry and the expression of cell-cycle proteins (i.e., p21, p27, and p53) was assessed. Univariate and multivariate analysis of predicting survival prognostic factors were performed.
RESULTS: The authors analyzed 88 patients with thymoma who underwent radical surgical resection at the study institution. According to the Masaoka staging system, 41 patients had Stage I disease, 31 patients had Stage II disease, and 16 patients had Stage III disease. There were 24 tumor recurrences (27.3%), 4 of which were local, 16 of which were distant intrathoracic, and 4 of which were extrathoracic. The second radical resection provided a disease-free survival rate that was similar to the first. Only Masaoka stage (P = 0.001), WHO classification (P=0.001), high expression of p53 (P=0.03), and low expression of p21 (P=0.02) and p27 (P=0.001) were found to be correlated with a reduced disease-free survival. Low p27 expression was found to be the most significant predictive factor of a short disease-free survival (P=0.001), especially when associated with low p21 expression and high p53 expression (P=0.0001).
CONCLUSIONS: Long-term disease-free survival in thymoma patients treated with radical surgical resection was found to be correlated with Masaoka stage, WHO classification, and expression of cell-cycle proteins, with the latter found to be the most significant predictive factor. Functional cooperation between cell-cycle proteins might constitute another level of regulation in tumor growth. More careful surveillance should be adopted whenever there is negative cell-cycle protein expression. Copyright 2005 American Cancer Society

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16206298     DOI: 10.1002/cncr.21433

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Tumour eosinophilia combined with an immunohistochemistry panel is useful in the differentiation of type B3 thymoma from thymic carcinoma.

Authors:  Thaer Khoury; Rameela Chandrasekhar; Gregory Wilding; Dongfeng Tan; Richard T Cheney
Journal:  Int J Exp Pathol       Date:  2010-11-02       Impact factor: 1.925

2.  A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study.

Authors:  Anish Thomas; Arun Rajan; Eva Szabo; Yusuke Tomita; Corey A Carter; Barbara Scepura; Ariel Lopez-Chavez; Min-Jung Lee; Christophe E Redon; Ari Frosch; Cody J Peer; Yuanbin Chen; Richard Piekarz; Seth M Steinberg; Jane B Trepel; William D Figg; David S Schrump; Giuseppe Giaccone
Journal:  Clin Cancer Res       Date:  2014-09-04       Impact factor: 12.531

3.  Prognostic value of immunohistochemical markers in malignant thymic epithelial tumors.

Authors:  Priska Leisibach; Didier Schneiter; Alex Soltermann; Yoshi Yamada; Walter Weder; Wolfgang Jungraithmayr
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

Review 4.  Thymic malignancies: from clinical management to targeted therapies.

Authors:  Ronan J Kelly; Iacopo Petrini; Arun Rajan; Yisong Wang; Giuseppe Giaccone
Journal:  J Clin Oncol       Date:  2011-11-21       Impact factor: 44.544

Review 5.  Expression of cell cycle and apoptosis regulators in thymus and thymic epithelial tumors.

Authors:  Alexandra Papoudou-Bai; Alexandra Barbouti; Vassiliki Galani; Kalliopi Stefanaki; Dimitra Rontogianni; Panagiotis Kanavaros
Journal:  Clin Exp Med       Date:  2015-03-21       Impact factor: 3.984

6.  Cyclin-dependent kinase inhibitors, p16 and p27, demonstrate different expression patterns in thymoma and thymic carcinoma.

Authors:  Mutsuko Omatsu; Toshiaki Kunimura; Tetsuya Mikogami; Akira Shiokawa; Atsuko Masunaga; Tomoko Nagai; Akihiko Kitami; Takashi Suzuki; Mitsutaka Kadokura
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-06-18

7.  Stage-based treatment for thymoma in due consideration of thymectomy: a single-center experience and comparison with the literature.

Authors:  Joerg Lindenmann; Nicole Fink-Neuboeck; Martin Pichler; Udo Anegg; Alfred Maier; Josef Smolle; Freyja Maria Smolle-Juettner
Journal:  World J Surg Oncol       Date:  2015-10-16       Impact factor: 2.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.